Exscientia Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 483

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $630M

  • Investors
  • 1

Exscientia General Information

Description

Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.

Contact Information

Website
www.exscientia.com
Formerly Known As
Exscientia Al Limited
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • The Schrödinger Building
  • Oxford Science Park
  • Oxford OX4 4GE
  • England, United Kingdom
Primary Industry
Drug Discovery
Parent Company
Exscientia (UK) Holdings
Vertical(s)
Big Data, Artificial Intelligence & Machine Learning, Life Sciences
Corporate Office
  • The Schrödinger Building
  • Oxford Science Park
  • Oxford OX4 4GE
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exscientia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 20-Nov-2024 $630M Completed Generating Revenue
11. PIPE 01-Oct-2021 Completed Generating Revenue
10. IPO 01-Oct-2021 Completed Generating Revenue
9. Later Stage VC 08-Sep-2021 Completed Profitable
8. Later Stage VC (Series D) 27-Apr-2021 Completed Profitable
7. Grant 09-Dec-2020 Completed Profitable
6. Later Stage VC 30-Oct-2020 Completed Profitable
5. Later Stage VC (Series B) 07-Jan-2019 Completed Profitable
4. Early Stage VC 11-Oct-2017 $17.6M $17.6M Completed Profitable
3. Secondary Transaction - Private 28-Sep-2017 $17.9M Completed Profitable
To view Exscientia’s complete valuation and funding history, request access »

Exscientia Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D1 Preference
Series D1 Preference
Series C1 Preference
Junior Series C Preference Shares
Series C Preference Shares
Ordinary B
Series B Preference Shares 29,408 $0.001382 $878.6 $878.6 1x $878.6 9.42%
Series A Prefernce Shares 30,255 $0.001382 $600.72 $600.72 1x $600.72 9.69%
To view Exscientia’s complete cap table history, request access »

Exscientia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery
Drug Discovery
Oxford, United Kingdom
483 As of 2023

South San Francisco, CA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exscientia Competitors (31)

One of Exscientia’s 31 competitors is X-37, a Venture Capital-Backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
X-37 Venture Capital-Backed South San Francisco, CA
insitro Venture Capital-Backed South San Francisco, CA
Genesis Molecular AI Venture Capital-Backed San Mateo, CA
Numerion Labs Venture Capital-Backed San Francisco, CA
Cyrus Biotechnology Venture Capital-Backed Seattle, WA
You’re viewing 5 of 31 competitors. Get the full list »

Exscientia Patents

  • 70

    Total Documents Applications and Grants

  • Total Patents Families

  • 15

    Granted

  • 7

    Pending

  • Expiring in next 12 mo

Exscientia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260138956-A1 Novel compounds and uses thereof Pending 20-Nov-2024
GB-202412464-D0 Novel compounds and uses thereof Inactive 23-Aug-2024
GB-202405991-D0 Drug design method using active learning over synthon space Inactive 29-Apr-2024
GB-202403045-D0 Nlrp3 modulators Inactive 01-Mar-2024
GB-202310945-D0 Nlrp3 modulators Inactive 17-Jul-2023
To view Exscientia’s complete patent history, request access »

Exscientia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exscientia Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Air Street Capital Venture Capital Minority
Blackrock Innovation Capital Group Growth/Expansion Minority
Bristol-Myers Squibb Corporation Minority
Casdin Capital Venture Capital Minority
Celgene Corporation Minority
You’re viewing 5 of 17 investors. Get the full list »

Exscientia Investments & Acquisitions (4)

Exscientia’s most recent deal was a Corporate Asset Purchase with Apeiron Biotechnology (Oral CDK7 Inhibitor Program) for . The deal was made on 19-Jul-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Apeiron Biotechnology (Oral CDK7 Inhibitor Program) 19-Jul-2024 Corporate Asset Purchase Buildings and Property
Allcyte 18-Aug-2021 Merger/Acquisition Other Healthcare Technology Systems
ENPP1 Program (Exscientia / Rallybio) 23-Jul-2019 Joint Venture Drug Discovery
Kinetic Discovery 15-Nov-2018 Merger/Acquisition Drug Discovery
To view Exscientia’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

Exscientia Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Kinetic Discovery Dundee, United Kingdom 2008

Exscientia FAQs

  • When was Exscientia founded?

    Exscientia was founded in 2012.

  • Where is Exscientia headquartered?

    Exscientia is headquartered in Oxford, United Kingdom.

  • What is the size of Exscientia?

    Exscientia has 483 total employees.

  • What industry is Exscientia in?

    Exscientia’s primary industry is Drug Discovery.

  • Is Exscientia a private or public company?

    Exscientia is a Private company.

  • What is the current valuation of Exscientia?

    The current valuation of Exscientia is .

  • What is Exscientia’s current revenue?

    The current revenue for Exscientia is .

  • How much funding has Exscientia raised over time?

    Exscientia has raised $874M.

  • Who are Exscientia’s investors?

    Air Street Capital, Blackrock Innovation Capital Group, Bristol-Myers Squibb, Casdin Capital, and Celgene are 5 of 17 investors who have invested in Exscientia.

  • Who are Exscientia’s competitors?

    X-37, insitro, Genesis Molecular AI, Numerion Labs, and Cyrus Biotechnology are some of the 31 competitors of Exscientia.

  • When was Exscientia acquired?

    Exscientia was acquired on 20-Nov-2024.

  • Who acquired Exscientia?

    Exscientia was acquired by Recursion Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process